Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study

Parkinson's Disease Clinical Trial

Official title:

An Open Label Conversion Study of Carbidopa-Levodopa (CD-LD) Extended-Release Taken Alone or in Combination With CD-LD Immediate Release to IPX066 Followed by an Open-Label Extension Safety Study of IPX066 in Advanced PD

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01411137
• Other study ID #: IPX066-B11-01
• Status: Completed
• Phase: Phase 3
• Start date: August 2011
• Est. completion date: March 2013

Study information

• Verified date: April 2017
• Source: Impax Laboratories, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study had three distinct parts and is described as follows:

Part 1:

• To evaluate the dose conversion from CD-LD ER taken alone or in combination with CD-LD IR to IPX066 in subjects with advanced PD

• To evaluate the utility of the Objective Parkinson's Disease Measurement (OPDM), an exploratory computer-based system, in assessing dexterity and mobility in a subset of PD subjects.

Part 2:

• To evaluate the long-term safety and clinical utility of IPX066 under open-label conditions in eligible subjects who successfully completed Part 1 of the study.

Part 3:

• To further evaluate the long-term safety of IPX066 in eligible subjects who successfully completed Part 2.

Description:

Part 1: This study was a multicenter, open-label study. Subjects were to be converted from their previous CD-LD treatment to IPX066 over a 6-week period. Up to 40 subjects were to be enrolled in the study. Enrollment was defined as subjects who received study drug in Part 1 - Visit 1. Subjects were to be entered into one of two cohorts.

Approximately 24 subjects were to enroll in Cohort 1 (non-OPDM subjects) and up to 16 subjects at selected sites were to enroll in Cohort 2 (OPDM subjects). For the subjects enrolled in Cohort 2, along with the OPDM measurements, PK blood samples were also to be collected.

Part 2: Following the successful completion of Part 1 of the study, eligible subjects could participate in Part 2, a 6-month open-label extension study.

Part 3: Following the successful completion of Part 2 of the study, eligible subjects could participate in Part 3, an additional 6-month open-label extension study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 43
• Est. completion date: March 2013
• Est. primary completion date: March 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years and older

Eligibility

Inclusion Criteria:

1. Diagnosed with idiopathic PD without any known cause for Parkinsonism.

2. At least 30 years old at the time of PD diagnosis.

3. Currently being treated with:

• an LD dosing frequency of at least four times a day

• at least one dose of CD-LD ER daily

• requiring a total daily LD dose of at least 400 mg

• stable regimen for at least 4 weeks prior to Screening

4. Concomitant therapy with amantadine, anticholinergics, selective monoamine oxidase (MAO) type B inhibitors (e.g., selegiline, rasagiline) or dopamine agonists is allowed as long as the doses and regimens have been stable for at least 4 weeks prior to Screening and the therapy is intended to be constant throughout the course of the study.

5. Agrees to use a medically acceptable method of contraception throughout the study and for 1 month after completing the study.

Exclusion Criteria:

1. Pregnant or breastfeeding

2. Diagnosed with atypical Parkinsonism or any known secondary Parkinsonian syndrome.

3. Nonresponsive to LD therapy.

4. Prior functional neurosurgical treatment for PD (e.g., ablation or deep brain stimulation) or if such procedures are anticipated during study participation.

5. Planning to take during participation in the clinical study: any controlled-release LD product, additional CD or benserazide, entacapone or tolcapone, nonselective MAO inhibitors, or antipsychotics including neuroleptic agents for the purpose of treating psychosis or bipolar disorder.

6. Any evidence of suicidal behavior within 6 months of entering the study.

7. Allergic or hypersensitive to to CD, LD, entacapone, riboflavin, Yellow Dye #5 (tartrazine), citrus fruit or grape juice.

8. History of or currently active psychosis.

9. Active or history of peptic ulcers or surgical procedure of the stomach, the small intestine or the large intestine.

10. Active or history of narrow-angle glaucoma.

11. History of malignant melanoma or a suspicious undiagnosed skin lesion.

12. History of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias, upper gastrointestinal hemorrhage, or neuroleptic malignant syndrome and/or nontraumatic rhabdomyolysis.

13. Abnormal kidney function

14. Severe hepatic impairment.

15. Received any investigational medications during the 4 weeks prior to Screening.

16. Previously enrolled in IPX066 studies.

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease

Intervention

Drug:
• IPX066
Subjects were converted from their current treatment to IPX066 over a 6-week period. Experimental Drug Product: IPX066 (carbidopa-levodopa) extended-release capsules

Locations

Country	Name	City	State
United States	Quest Research Institute	Bingham Farms	Michigan
United States	University of Alabama at Birmingham	Birmingham	Alabama
United States	Parkinson's Disease and Movement Disorders Center of Long Island	Commack	New York
United States	Coastal Neurological Medical Group	La Jolla	California
United States	University of Nevada School of Medicine	Las Vegas	Nevada
United States	Wisconsin Institute for Neurologic and Sleep Disorders	Milwaukee	Wisconsin
United States	Renstar Medical Research	Ocala	Florida
United States	The Parkinson's Institute	Sunnyvale	California

Sponsors (2)

Lead Sponsor	Collaborator
Impax Laboratories, LLC	Michael J. Fox Foundation for Parkinson's Research

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Patient Global Impression (PGI)	At Part 1 Week 6, Part 2 Month 3 and Month 6 or at Early Termination, the subjects rated the change in their condition with IPX066 treatment from their condition prior to Part 1 Visit 1(Baseline) using Patient Global Impression (PGI) 7-point scale. 1=very much worse and 7=very much improved.	6 months
Primary	Clinical Global Impression (CGI)	Clinician-reported satisfaction outcome of IPX066 using Clinical Global Impression (PGI) 7-point scale.; At Part 1 Week 6; Part 2 Month 3, and Month 6 or at Early Termination, the Investigator rated how much a subject's overall condition had changed since Part 1 Visit 1 (Baseline) using 7-point scale. 1=very much worse and 7=very much improved.	6 months
Primary	Parkinson's Disease Questionnaire-8 (PDQ-8)	Change from Baseline in Parkinson's disease Questionnaire-8 (PDQ-8) at End of Study or early discontinuation. The PDQ-8 is a self-reported questionnaire consisting of 8 questions regarding the subject's disease symptoms, each item ranging from 0 to 4, and the responses consist of 0=Never, 1=Occasionally, 2=Sometimes, 3=Often, and 4=Always or cannot do at all, total score ranging from 0 (never have problems/issues) to 32 (always have problems or cannot do at all).	6 months